Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01186185 · ClinicalTrials.gov registry record · Early Phase 1
Fludrocortisone for Sudden Hearing Loss
A Early Phase 1 study, sponsored by Oregon Health and Science University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT01186185 is a Early Phase 1 study that was terminated before completion, run by Oregon Health and Science University. The registered enrollment target is 5 participants.
The verdict
NCT01186185, a Early Phase 1 study, was terminated before completion, sponsored by Oregon Health and Science University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The standard of care treatment of sudden hearing loss uses a type of steroid called glucocorticoid. Examples of glucocorticoids are prednisone, methylprednisolone and dexamethasone. Not everybody recovers hearing with glucocorticoid treatment. Fludrocortisone is a different type of steroid called mineralocorticoid. Unlike glucocorticoids, which work by reducing inflammation, mineralocorticoids work by changing salt and fluid balance. In animal studies, fludrocortisone is at least as effective as glucocorticoid in preserving hearing. Fludrocortisone is not approved for the treatment of sudden hearing loss. The purpose of this study is to test whether fludrocortisone can treat sudden hearing loss.
Interventions
- DRUG Fludrocortisone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-08 |
| Est. Completion | 2016-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01186185
The ClinicalTrials.gov registry entry for NCT01186185 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fludrocortisone is the first listed.
NCT01186185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01186185 about?
NCT01186185 is a clinical study titled "Fludrocortisone for Sudden Hearing Loss". The standard of care treatment of sudden hearing loss uses a type of steroid called glucocorticoid. Examples of glucocorticoids are prednisone, methylprednisolone and dexamethasone. Not everybody recovers hearing with glucocorticoid treatment. Fludrocortisone is a different type of steroid called mi...
What is the current status of trial NCT01186185?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2012-08. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01186185?
The interventions under investigation include: Fludrocortisone (DRUG).
Who is sponsoring clinical trial NCT01186185?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.